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D
espite recent advances in treatment, heart failure (HF) has devastating effects on survival (1) and quality of life (2) .
Pharmacological therapy consists of diuretics and neurohormonal modulating agents. It is well established that energy deficiency contributes to the syndrome of HF (3) , and this has been proposed as a therapeutic target.
In previous phase 2 studies, beneficial effects of perhexiline have been observed in refractory angina (4) , HF (5) , and hypertrophic cardiomyopathy (6) . This is subject to variable metabolism by P4502D6, of which there are several polymorphic variants.
Sustained high plasma levels may lead to hepatotoxicity and neurotoxicity due to phospholipid accumulation in these tissues.
It has been shown that toxicity is avoided by plasma monitoring with dose titration (7) .
The therapeutic effects of perhexiline have been believed to relate to altered cardiac substrate utilization. Perhexiline has been shown to inhibit carnitine palmitoyltransferase 1 and, to a lesser extent, carnitine palmitoyltransferase 2 (8) . These mitochondrial enzymes facilitate entry of medium-and long-chain fatty acids into mitochondria to undergo beta-oxidation and subsequently produce adenosine triphosphate (ATP). This inhibition of fatty acid metabolism may be expected to lead to a reciprocal increase in carbohydrate activation (via allosteric activation of the enzyme pyruvate dehydrogenase) and thus an improvement in myocardial efficiency and phosphocreatine (PCr)/ATP ratio.
31 P cardiac magnetic resonance spectroscopy ( 31 P MRS) allows noninvasive quantification of the PCr/ATP ratio, which is an accepted measure of cardiac energetic status. It has been shown that the PCr/ATP ratio is reduced in the failing human heart (9, 10) . Therefore, we sought to determine whether the therapeutic benefit of perhexiline in HF is related to an improved cardiac PCr/ATP ratio and whether this is a consequence of altered cardiac substrate utilization. Effective therapy for HF that does not act in the first instance by direct effects on cardiac metabolism may nevertheless in the longer term result in improvements in the cardiac PCr/ATP ratio via an improvement in HF syndrome, leading in turn to molecular reverse remodeling of maladaptive changes in genes involved in cardiac metabolism and calcium handling and thereby potentially to a virtuous cycle of improved cardiac function (11) (12) (13) . In this study, we hypothesized that perhexiline therapy would improve the cardiac PCr/ATP ratio in patients with HF by altering cardiac substrate utilization. To assess whether these changes occur early and are by inference directly responsible for the subsequent improvement in cardiac function, we used a short- Beadle et al. Plasma concentrations of NT-proBNP were determined using an immunoluminometric assay (15) . Patients who had plasma triglyceride levels >2.5 mmol/l were assumed not to have fasted, and their samples were excluded from analysis of insulin and metabolites.
M y o c a r d i a l e n e r g e t i c s . Cardiac high-energy phosphate metabolism was measured using 31 P MRS on a (17) .
Beadle et al. A total of 1,637 patients were screened for inclusion, 278 met the inclusion criteria, and 50 were randomized. One patient was lost to follow-up.
Twenty-two patients in each group underwent cardiac 31 P MRS. CONSORT ¼ Consolidated Standards of Reporting Trials; MRS ¼ magnetic resonance spectroscopy; SNR ¼ signal-to-noise ratio.
Improvement in Cardiac Energetics by Perhexiline Blood samples for oxygen were taken in blood gas syringes, and measurement of oxygen was performed using a Bayer Rapidlab 800 series blood gas analyzer (Bayer Healthcare LLC, East Walpole, Massachusetts).
Measurement of carbon dioxide was performed off site with isotope-ratio mass spectrometry using a Thermo Finnigan Delta XP isotope ratio mass spectrometer (Thermo Fisher Scientific UK, Loughborough, England). ACE-I/ARBs ¼ angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; ATP ¼ adenosine triphosphate; LVEF ¼ left ventricular ejection fraction; MLWHFQ ¼ Minnesota Living With Heart Failure Questionnaire; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; NYHA ¼ New York Heart Association; PCr ¼ phosphocreatine.
S t a t i s t i c

FIGURE 2 Monitoring of Perhexiline Levels
Perhexiline levels were measured in all patients at the end of the first week and again at the conclusion of the intervention period. The dose of perhexiline was adjusted according to the level in the first week. Abbreviations as in Table 1 . PCr ¼ phosphocreatine; other abbreviation as in Figure 1 .
FI GUR E 4 Change in PCr/ATP Ratio Between Baseline and Follow-Up
The PCr/ATP ratio was not well matched between groups at baseline. There was a significant increase in the PCr/ATP ratio with perhexiline therapy from 1.16 AE 0.39 to 1.51 AE 0.51 compared with placebo (p < 0.001). Abbreviations as in Figure 3 .
Improvement in Cardiac Energetics by Perhexiline -2 0 1 5 : ---are shown in Figure 5 . The mean CRLBs for PCr and ATP for the entire group were 10.7% and 12.7%, respectively, indicating a satisfactory signal-to-noise ratio (20) . Three patients were excluded from the initial analysis because of a poor signal-to-noise ratio (CRLBs >20%). Table 2 ).
ECHOCARDIOGRAPHY. There was no change in the secondary endpoint of LVEF in the perhexiline group This showed no change in peak global systolic strain or strain rate between the groups. Rotational strain analysis was available in 24 patients (perhexiline: 13;
placebo: 11) and showed no change in either absolute twist or twist rate (data not shown).
VENOUS BLOOD METABOLITES AND NT-proBNP
LEVELS. After the intervention, there were no differences in venous metabolites, NT-pro-BNP levels, or insulin levels between the groups (Tables 2 and 3) .
CROSS-HEART METABOLISM. Cross-heart sampling from the invasive studies did not show a group difference in metabolite extraction ( Table 4) . The respiratory quotient was similar between the groups (perhexiline: 0.86 AE 0.06; placebo: 0.90 AE 0.16; p ¼ 0.63). In the cross-heart sampling group, perhexiline therapy was associated with an increase in the PCr/ATP ratio of 0.51 AE 0.18, whereas placebo was associated with a reduction in the PCr/ATP ratio of 0.1 AE 0.16 (p < 0.005 for between-group difference).
ADVERSE EFFECTS. Adverse effects included nausea (n ¼ 3), dizziness (n ¼ 1), and diarrhea (n ¼ 1) in the perhexiline group and headaches (n ¼ 1), lethargy (n ¼ 1), and metallic taste in the mouth (n ¼ 1) in the placebo group. There were no instances of hepatotoxicity and no deaths or major adverse events during the study period. In the perhexiline group, 2 patients had subtherapeutic levels, and 2 patients had levels above the therapeutic level at the end of the study period ( Figure 2) .
DISCUSSION
This is the first study to show that short-term perhexiline therapy leads to an improvement in cardiac energetics without a shift in substrate utilization.
Importantly, this was associated with an improvement in NYHA functional class.
We have previously shown that perhexiline leads to an improvement in the PCr/ATP ratio in patients with hypertrophic cardiomyopathy after 5 months of therapy (6) . In the present study, the effects of perhexiline on the PCr/ATP ratio were observed by 1 month of therapy with a regimen that typically takes approximately 2 weeks to achieve therapeutic levels.
This marked change in energetics is thus an early phenomenon, occurring before any demonstrable effect on resting cardiac performance, which is consistent with this being a direct effect of the drug on cardiac energetics rather than an improvement due to a longer-term improvement in the HF syndrome with consequent molecular reverse remodeling.
An important finding of this study is that the improvement in cardiac energetics with perhexiline occurs without any evidence of altered whole blood substrate levels. Furthermore, we did not see any difference in cross-heart substrate gradients or in cross-heart RER between the perhexiline and placebo groups. This is important because the latter provides a measure of relative substrate utilization (carbohydrate vs. fatty acids) derived from both uptake from plasma and from cardiac stores. A lower fatty acid oxidation and a greater reliance on carbohydrate oxidation would be expected to have manifested as a higher cross-heart RER. There was no significant difference between the groups, but the mean RER was actually lower in the perhexiline group. These find- STUDY LIMITATIONS. The number of patients was small and was not well matched at baseline, with those randomized to perhexiline having more severe HF, which could have had a significant impact on the baseline substrate utilization. Furthermore, for ethical reasons, it was not possible to submit patients to invasive studies before and after the intervention, which clearly would have been more robust. Nevertheless, given the substantial improvement in cardiac Values are mean AE SD.
Abbreviation as in Table 3 .
energetics observed in these patients, we would have expected to see a difference in the on-treatment crossheart substrate uptake and/or respiratory quotient if perhexiline were working through such a mechanism.
In our hands, the coefficient of variation for the measurement of RER was 9%. Although this was a secondary endpoint and our power calculations were on the basis of the primary endpoint, our sample size 
